SEC Form 4 · accession 0001209191-19-015085
PhaseBio Pharmaceuticals Inc · PHAS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard van den Broek
Director
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001169245
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-employee Director Stock Option (right to buy)F1 | $3.15 | Feb 27, 2019 | A | 22,000 | A | — | Feb 27, 2029 | Common Stock | 22,000 | 22,000 | D |
| Non-employee Director Stock Option (right to buy)F1 | $3.15 | Feb 27, 2019 | A | 23,000 | A | — | Feb 27, 2029 | Common Stock | 23,000 | 23,000 | D |
Explanation of responses
- F1The shares subject to the option shall vest in equal monthly installments over 36 months from February 27, 2019, subject to the reporting person's continued service through each such date.